{
    "clinical_study": {
        "@rank": "85539", 
        "arm_group": [
            {
                "arm_group_label": "Sevelamer carbonate", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site."
            }
        ], 
        "brief_summary": {
            "textblock": "The study aims to evaluate the efficacy and safety of sevelamer carbonate in reducing serum\n      phosphorus and serum lipids (total and LDL-cholesterol) in Chronic Kidney Disease Patients\n      on dialysis."
        }, 
        "brief_title": "Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis", 
        "completion_date": {
            "#text": "September 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Chronic Kidney Disease on Hemodialysis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  On hemodialysis regimen scheduled for four hour duration three times per week for a\n             minimum 30 days prior to Visit 1 and throughout the study\n\n          -  Have a central laboratory serum iPTH measurement less than 1000 pg/mL at Visit 1\n\n          -  Have a central laboratory serum phosphorus measurement greater than 5.5 mg/dL at\n             Visit 1a\n\n        Exclusion Criteria:\n\n          -  Active dysphagia or swallowing disorder; or a predisposition to or current bowel\n             obstruction, ileus, or severe gastrointestinal (GI) motility disorders including\n             severe constipation\n\n          -  Documented poorly controlled diabetes mellitus, poorly controlled hypertension,\n             active vasculitis, human immunodeficiency virus infection, or any clinically\n             significant unstable medical condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "205", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736150", 
            "org_study_id": "SVCARB03808"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.\nIf serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sevelamer carbonate", 
                "description": "Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.\nIf serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals.", 
                "intervention_name": "Sevelamer carbonate", 
                "intervention_type": "Drug", 
                "other_name": "Renvela"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sevelamer"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Hemodialysis", 
        "lastchanged_date": "November 26, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Peking University First Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "West China Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "Sichuan Provincial People's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "Southwest Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Guangzhou First Municipal People's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Nanfang Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Sun Yat-Sen University School of Medicine 1st Affiliated Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "Zhejiang University School of Medicine 1st Affiliated Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }, 
                    "name": "Zhongda Hospital of Southeast University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }, 
                    "name": "Jiangsu Province Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China"
                    }, 
                    "name": "Qingdao Municipal Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Renji Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Changzheng Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Zhongshan Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Xinhua Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Shanghai Ruijin Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China"
                    }, 
                    "name": "Wenzhou College of Medicine 1st Affiliated Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis", 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline to Visit 6/Early Termination (ET) in serum phosphorous.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Frequency of treatment-emergent adverse events (AEs) and serious adverse events (SAEs), changes in laboratory parameters, and changes in vital signs.", 
                "safety_issue": "Yes", 
                "time_frame": "11 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736150"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline to Visit 6/ET in serum lipids (total cholesterol and LDL-cholesterol).", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Genzyme, a Sanofi Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}